Lenalidomide maintenance in Myeloma - a goldilocks problem?

Melissa Ng Liet Hing¹, Amit Khot^{1

2}

Affiliations

¹ Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Victoria, Australia.
² Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.

Comment

Melissa Ng Liet Hing et al. Leuk Lymphoma. 2023 Oct.

. 2023 Oct;64(10):1611-1614.

doi: 10.1080/10428194.2023.2255325. Epub 2023 Sep 6.

Melissa Ng Liet Hing¹, Amit Khot^{1

2}

¹ Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Victoria, Australia.
² Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.

No abstract available

Comment on

B-cell acute lymphoblastic leukemia after lenalidomide maintenance therapy; a deleterious adverse event that needs further investigation. Report of three cases and review of the literature.
Arribas I, Maluquer C, Pomares H, Carro I, Baca C, Bosch A, Arévalo CE, Montané C, Ribes-Amorós J, Zamora L, Granada I, Gamundi E, Arnan M, Sureda A. Arribas I, et al. Leuk Lymphoma. 2023 Oct;64(10):1701-1705. doi: 10.1080/10428194.2023.2234527. Epub 2023 Jul 17. Leuk Lymphoma. 2023. PMID: 37455651 Review. No abstract available.